Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports on cancer vaccines findings from S.F. Slovin and co-researchers provide new insights
April 2nd, 2008
According to recent research published in the Cancer Journal, "Immunotherapy with vaccines, cytokines, and monoclonal antibodies against checkpoint molecules has been introduced into the clinical arena. Although all have demonstrated safety in clinical trials in patients with castrate metastatic prostate cancer, no one approach has been able to provide improved overall survival." "This article is a review of the current issues and potential resolutions as to how we might go forward in developing and interpreting immunologic trials. Phase I, II, and III trials showed that immunologic tolerance can be abrogated against specific tumor-associated antigens, but the...
Source: Vaccine Weekly (2008-04-02)
|
